Cedazuridine 100 mg / decitabine 35 mg Oral Tablet
RxNorm 2384457
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2384457 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: cedazuridine 100 mg / decitabine 35 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Cedazuridine 100 mg / decitabine 35 mg Oral Tablet
(Atom ID: 12415822)
PSNPrescribable
Prescribable Name (PSN):
Cedazuridine 100 mg / decitabine 35 mg Oral Tablet
(Atom ID: 12416348)
PTPrescribable
Designated preferred name (PT):
Cedazuridine 100 mg and decitabine 35 mg oral tablet
(Atom ID: 12536648)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely cedazuridine 100 mg and decitabine 35 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12537597)
Patient Education
Decitabine and Cedazuridine
The combination of decitabine and cedazuridine is used to treat certain types of myelodysplastic syndrome (conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells), including chronic myelomonocytic leukemia (CMML) in adults. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect.
[Learn More]
* Please review the disclaimer below.